Table 7 Change in fatigue in lean, overweight and obese patients versus change in adipokines, IGF-1 and neuropeptides
From: Exercise and obesity in fibromyalgia: beneficial roles of IGF-1 and resistin?
Lean patients | ∆MFIGF 30 wks | ∆Adiponectin 30 wks | ∆Leptin 30 wks | ∆Resistin 30 wks | ∆Free IGF-1 30 wks | ∆Tot IGF-1 30 wks | ∆IGFB3 30 wks | ∆NPY 30 wks | ∆NGF 30 wks | |
|---|---|---|---|---|---|---|---|---|---|---|
∆FIQ Fatigue 30 weeks | r P n | 0.268 0.521 8 | 0.541 0.210 7 | -0.432 0.333 7 | -0.685 0.090 7 | 0.145 0.784 6 | 0.812 0.05 6 | 0.086 0.872 6 | 1.000 2 | 1.000 2 |
∆MFIGF 30 weeks | r P n | 1.000 8 | 0.275 0.550 7 | -0.220 0.635 7 | -0.239 0.606 7 | 0.059 0.912 6 | 0.706 0.117 6 | 0.177 0.738 6 | 1.000 2 | 1.000 2 |
Overweight patients | ∆MFIGF 30 wks | ∆Adiponectin 30 wks | ∆Leptin 30 wks | ∆Resistin 30 wks | ∆Free IGF-1 30 wks | ∆Tot IGF-1 30 wks | ∆IGFB3 30 wks | ∆NPY 30 wks | ∆NGF 30 wks | |
∆FIQ Fatigue 30 wks | r P n | 0.530 0.008 24 | -0.219 0.315 23 | -0.099 0.654 23 | 0.270 0.213 23 | -0.021 0.924 22 | 0.213 0.380 19 | 0.260 0.232 23 | 0.394 0.164 14 | -0.475 0.086 14 |
∆MFIGF 30 wks | r P n | 1.000 24 | -0.089 0.685 23 | 0.127 0.562 23 | -0.265 0.222 23 | -0.233 0.297 22 | -0.012 0.962 19 | 0.104 0.635 23 | 0.384 0.176 14 | -0.047 0.874 14 |
Obese patients | ∆MFIGF 30 wks | ∆Adiponectin 30 wks | ∆Leptin 30 wks | ∆Resistin 30 wks | ∆Free IGF-1 30 wks | ∆Tot IGF-1 30 wks | ∆IGFB3 30 wks | ∆NPY 30 wks | ∆NGF 30 wks | |
∆FIQ Fatigue 30 wks | r P n | 0.283 0.373 12 | -0.753 0.019 9 | 0.084 0.831 9 | -0.326 0.391 9 | -0.711 0.032 9 | -0.261 0.498 9 | 0.072 0.878 7 | 0.154 0.805 5 | -0.205 0.741 5 |
∆MFIGF 30 wks | r P n | 1.000 12 | -0.210 0.587 9 | 0.647 0.060 9 | -0.815 0.007 9 | -0.025 0.949 9 | -0.418 0.263 9 | 0.786 0.036 7 | -0.900 0.037 5 | 0.500 0.391 5 |